Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States
Among patients with HF in contemporary US clinical practice, patients prescribed vericiguat have distinct demographic and clinical profiles compared to eligible patients not prescribed vericiguat. Future research should confirm these findings and explore whether subgroups of eligible patients less likely to be prescribed vericiguat may benefit from targeted implementation initiatives.
Authors
- Sophie Barlow (ORCID: https://orcid.org/0000-0001-5604-1360)
- Stephen John Greene (ORCID: https://orcid.org/0000-0001-6912-7374)
- N Engels (ORCID: https://orcid.org/0000-0002-1807-3465)
- Andrá S. Stevenson
- Catelyn Coyle
- Kathryn Tebbs (ORCID: https://orcid.org/0000-0001-8633-3153)
- Louise Hancock
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- Clinical Research Institute (US)
- Adelphi Group (United Kingdom) (GB)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fcvm.2025.1633435
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00